Remdesivir results pile up, but what do they all mean?
The latest addition to remdesivir’s Covid-19 dataset paints a confusing picture, but it's not necessarily bad.
The winds change again for Gilead and remdesivir
A world desperate to know whether remdesivir will blunt Covid-19 received another hint today, and this time the news was more encouraging.
Long term forecasts confirm Keytruda’s dominance
Keytruda sales could be more than double any other product in 2026, new estimates suggests, as Merck’s cancer drug surges into the record books.
Kevzara's Covid-19 setback shows need for hard evidence
As investors continue to jump on small sparks of hope in the pandemic pipeline Sanofi and Regeneron inject a dose of reality.
One leak good, two leaks bad for Gilead
Skittish investors overreact to incomplete Covid-19 data once more – this time in the opposite direction.
Covid-19’s clinical damage starts to emerge
170 commercial trials were suspended in March while new patient starts slumped 65% as the pandemic swept the globe. April could look even worse.
Covid-19 antibody tests face a very specific problem
With the prevalence of coronavirus infection running at about 5%, test manufacturers and regulators alike will have to guard against false positives.
Covid-19 adds a new danger to drug launches
Launch phase is a challenging time for drug developers, so consider the likes of Biohaven, Esperion and, most recently, Urogen, as they brave locked-down markets.
New Covid-19 test and a decent first quarter buoy Abbott
Diagnostics prove defensive for Abbott, as the company jumps the FDA’s gun with its third coronavirus test.
Quidel wins the Covid-19 antigen test race
Antigen tests are faster and cheaper than viral RNA assays, but are notably less accurate.
Can Gilead make remdesivir pay?
Gilead has been rewarded handsomely, via share price gains, for its Covid-19 remdesivir work, but the potential costs should not be forgotten.
Roche takes on Abbott in Covid-19 antibody testing
Robust specificity data mark Roche’s serological test out as a major competitor.
Lonza to do the heavy lifting for Moderna’s Covid-19 vaccine
Moderna becomes the latest coronavirus vaccine player to act on the need for a major manufacturing push.
The crucial trials Medtronic has had to pause
Covid-19 could mean Medtronic loses out to Abbott, its rival in the mitral valve space.
Remdesivir results pile up, but what do they all mean?
The latest addition to remdesivir’s Covid-19 dataset paints a confusing picture, but it's not necessarily bad.
